VANCOUVER, BC, Canada, June 5, 2026 – TheNewswire — Noveris Health Sciences Inc. (CSE: NVRS | FSE: 0NF0 | OTC: MYCOF) (“Noveris” or the “Company”) is pleased to provide this corporate update.

 

Re-Engagement with Applied Pharmaceutical Innovation

 

The Company is pleased to announce that it has re-engaged Applied Pharmaceutical Innovation (“API”), one of Canada’s largest life sciences commercialization organizations, with operations at multiple sites in Alberta, to provide consulting services focused on psilocybin product development, the discovery of novel compounds, and the identification and protection of related intellectual property, including potential patent applications. The engagement is governed by a master services agreement effective May 27, 2026 (the “Services Agreement”).

 

The Company initially established its strategic partnership with API in June 2020, but was unable to continue the engagement following funding constraints that resulted in the project being paused in November, 2024. API remains an ideal partner to support the Company’s objectives of discovering, developing and optimizing intellectual property within the psilocybin sector as well as any other areas of drug development pursued by the Company, particularly with API’s significantly expanded research facilities and operations that have grown over the past 2 years to include global-scale commercial manufacturing. Accordingly, the Company is pleased to announce the re-engagement of API and payment of a $20,000 retainer pursuant to the Services Agreement to recommence the parties’ collaborative development efforts.  API retains ownership of certain work product related to its previously engagement with the Company, and as part of the new engagement will be providing recommendations on assets to transfer back to the Company.

 

In addition to the retainer, the Company has budgeted a minimum of $100,000 for research and development consultancy services from API (to be invoiced based on  hourly rates) under the Services Agreement during its fiscal year ending December 31, 2026. The Services Agreement does not impose a minimum (or maximum) spend requirement on the Company.

 

Applied Pharmaceutical Innovation is an industry-funded, not-for-profit life sciences commercialization organization that provides commercialization, development and strategic support services on a fee-for-service basis. API's engagement is expected to focus on assisting the Company with the evaluation, development, protection, and potential commercialization of intellectual property opportunities. API is not being granted ownership of Company intellectual property, nor any royalty, licensing or commercialization rights in respect of such intellectual property as part of the current engagement.

 

Update on its Stem Cell Initiatives

While management views opportunities in the stem cell and regenerative medicine sectors as complementary to the Company's broader life sciences focus, the Company believes that its immediate priority is to advance and maximize the value of its existing intellectual property portfolio and its renewed collaboration with API.

 

As previously announced on April 29, 2026, the Company entered into a non-binding term sheet contemplating the acquisition of an equity interest in Ell Stem Cells ("Ell"), a distributor of regenerative medicine products, including extracellular matrices, exosomes and stem cell-based therapies, to physicians from licensed laboratories. The Company remains in discussions with the vendors of Ell regarding potential avenues to participate in the stem cell distribution market and is evaluating a range of transaction structures, including a joint venture, licensing arrangement, strategic partnership, or equity investment. No definitive agreement has been entered into at this time, and as noted in the Company’s April 29th news release, there can be no assurance that any transaction will be completed.  Management will provide further updates on its stem cell initiatives as they become available.

    

About Noveris Health Sciences Inc.

Noveris Health Sciences Inc. (CSE: NVRS | FSE: 0NF0 | OTC: MYCOF) is a publicly traded biopharmaceutical and life sciences company focused on the research, development, and commercialization of next-generation medications and therapies to address mental health disorders, including nicotine addiction and post-traumatic stress disorder (PTSD).

   

Cautionary Statement Regarding Forward-Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws, including National Instrument 51-102 Continuous Disclosure Obligations. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company’s re-engagement with API, the Company’s drug development pipeline and future development activities, the anticipated advancement of the Company’s proprietary compound families toward clinical development, the Company’s expectations regarding future corporate and regulatory milestones, and the Company’s business initiatives in the stem cell industry. Forward-looking statements are based on assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions, and expected future developments, as well as other factors the Company believes are appropriate in the circumstances.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks include, but are not limited to, risks associated with the development and regulatory approval of drug candidates, including those subject to Health Canada and FDA review; the speculative nature of biopharmaceutical research and development; the Company’s ability to obtain and maintain necessary permits, licences, and approvals; the availability of financing on acceptable terms; the loss of key personnel; and general business and economic conditions. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

 

Additional Regulatory Note — Life Sciences

The Company’s drug development programs are subject to regulatory oversight by Health Canada and other applicable regulatory authorities. This re-engagement with API does not constitute approval of any drug candidate, nor does it represent a change in the regulatory status of any compound in the Company’s pipeline. There can be no assurance that any drug candidate will receive regulatory approval or be successfully commercialized.

 

Exchange Disclaimer

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

   

Investor & Media Contact

Noveris Health Sciences Inc.

Jason Birmingham

President & Chief Executive Officer

Tel: +1 778-900-NVRS (6877)

Email: fair@noveris.health

Web: http://noveris.health

 

Investor Relations

Fairfax Partners Inc.

Tel: +1 604 366 6277

Email: connect@fairfax.partners